Important note: Information in this article was accurate in 1986. The state of the art may have changed since the publication date.
IMMUNODEFICIENCY, AUTOIMMUNITY, AND MALIGNANCY
Dev Oncol; 21:125-45 1985. Unique Identifier : AIDSLINE ICDB/86620635 French MA; Univ. Dept. of Medicine, Northern General Hosp., Sheffield S5; 7AU, England
Abstract:
Studies performed over the last two decades have demonstrated an increased incidence of malignancy in primary immunodeficiency diseases; however, it has also become clear that the concept of immune surveillance cannot be fully accepted on the evidence from these studies. The types of malignancy that occur as a complication of some immunodeficiency diseases are similar to those that may complicate some autoimmune diseases, particularly connective tissue diseases. It is perhaps in this common ground that some mechanisms operating in the development of malignancy in these immunological diseases can be studied. To this end, the present chapter considers the malignant complications of various primary immunodeficiency diseases and connective tissue diseases, particularly in relation to the immunological abnormalities. Sections of the chapter have the following headings: primary immunodeficiency and malignancy (sex-linked hypogammaglobulinemia; common variable immunodeficiency; thymoma and immunodeficiency; selective IgA deficiency; selective IgM deficiency; severe combined immunodeficiency syndrome; immunodeficiency syndrome; immunodeficiency involving T-cells, phagocytes, or NK-cells; Wiskott-Aldrich syndrome; immunodeficiency in 'chromosome breakage syndromes'; X-linked lymphoproliferative syndrome; acquired immunodeficiency syndrome); autoimmune disease and malignancy (Sjogren's syndrome, systemic lupus erythematosus, rheumatoid arthritis, progressive systemic sclerosis, dermatomyositis and polymyositis); and general comments on the occurrence of malignancy in immunodeficiency and autoimmune disease. The authors conclude that an increased tendency for malignant changes to occur, rather than a decreased capacity to eliminate malignant cells through immunologic surveillance mechanisms, seems to be the most likely mechanism of oncogenesis in patients with immunodeficiency disease or autoimmune disease; support is presented for this conclusion. (104 Refs)
Keywords: Acquired Immunodeficiency Syndrome/COMPLICATIONS Agammaglobulinemia/COMPLICATIONS Ataxia Telangiectasia/COMPLICATIONS/GENETICS Autoimmune Diseases/*COMPLICATIONS Bibliography Bloom Syndrome/COMPLICATIONS/GENETICS Chromosome Aberrations Chromosome Abnormalities Fanconi's Anemia/COMPLICATIONS/GENETICS Human IgA/DEFICIENCY Immunologic Deficiency Syndromes/*COMPLICATIONS/GENETICS Killer Cells, Natural/IMMUNOLOGY Lupus Erythematosus, Systemic/COMPLICATIONS Lymphoproliferative Disorders/COMPLICATIONS/GENETICS Myositis/COMPLICATIONS/IMMUNOLOGY Neoplasms/*ETIOLOGY/IMMUNOLOGY Phagocytes/IMMUNOLOGY T-Lymphocytes/IMMUNOLOGY Thymus Neoplasms/ETIOLOGY Wiskott-Aldrich Syndrome/IMMUNOLOGY JOURNAL ARTICLE BIBLIOGRAPHY
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1986. The state of the art may have changed since the publication date.
